1246213-33-1

Basic information

• Product Name: Carbonic acid, 5-[[(1,4-dihydro-4-oxo-3-quinolinyl)carbonyl]aMino]-4-(1,1-diMethylethyl)-2-[2-[(Methoxycarbonyl)oxy]-1,1-diMethylethyl]phenyl Methyl ester
• Synonyms: Carbonic acid, 5-[[(1,4-dihydro-4-oxo-3-quinolinyl)carbonyl]aMino]-4-(1,1-diMethylethyl)-2-[2-[(Methoxycarbonyl)oxy]-1,1-diMethylethyl]phenyl Methyl ester
• CAS NO: 1246213-33-1
• Molecular Formula: C₂₈H₃₂N₂O₈
• Molecular Weight: 524.56228
• Mol File: 1246213-33-1.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Carbonic acid, 5-[[(1,4-dihydro-4-oxo-3-quinolinyl)carbonyl]aMino]-4-(1,1-diMethylethyl)-2-[2-[(Methoxycarbonyl)oxy]-1,1-diMethylethyl]phenyl Methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbonic acid, 5-[[(1,4-dihydro-4-oxo-3-quinolinyl)carbonyl]aMino]-4-(1,1-diMethylethyl)-2-[2-[(Methoxycarbonyl)oxy]-1,1-diMethylethyl]phenyl Methyl ester(1246213-33-1)
• EPA Substance Registry System: Carbonic acid, 5-[[(1,4-dihydro-4-oxo-3-quinolinyl)carbonyl]aMino]-4-(1,1-diMethylethyl)-2-[2-[(Methoxycarbonyl)oxy]-1,1-diMethylethyl]phenyl Methyl ester(1246213-33-1)

Safety Data

• Hazardous Substances Data: 1246213-33-1(Hazardous Substances Data)

Upstream product

• 1246213-30-8 2-(2-hydroxy-5-tert-butylphenyl)-2-methylpropan-1-ol 
• 1246213-32-0 5-amino-4-(tert-butyl)-2-(1-((methoxycarbonyl)oxy)-2-methylpropan-2-yl)phenyl methyl carbonate 
• 13721-01-2 4-oxo-1,4-dihydroquinoline-3-carboxylic acid 

Downstream Products

• 1246213-23-9 N-(2-(tert-butyl)-5-hydroxy-4-(1-hydroxy-2-methylpropan-2-yl)phenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide 

Relevant articles and documents

Altering metabolic profiles of drugs by precision deuteration 2: Discovery of a deuterated analog of ivacaftor with differentiated pharmacokinetics for clinical development

Ivacaftor is currently used for the treatment of cystic fibrosis as both monotherapy (Kalydeco; Vertex Pharmaceuticals, Boston, MA) and combination therapy with lumacaftor (Orkambi; Vertex Pharmaceuticals). Each therapy targets specific patient population

PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR

The invention provides a process for the preparation of a compound of Formula 1; comprising coupling a carboxylic acid of Formula 2; with an aniline of Formula 3; in the presence of a coupling agent.